Navigating the EU's Sweeping REACH Requirements: Nov. 30 Deadline Could Affect your Ability to Do Business

$427.00
Quantity Discounts
1 - 9999
$427.00
1 - 9999
$427.00
1 - 9999
$627.00
In this 90-minute Encore presentation, European legal experts Cándido García Molyneux and Peter Bogaert will take attendees step-by-step through the new regulation and advise them on how to determine if their products require registration under the five categories related to drug and medical devices.

Sign up your entire team to listen in and discover:

  • The REACH regulation’s potential impact on drug and device companies
  • How best to determine if your products or source materials meet the requirements for registration
  • What substances can be registered in accordance with the European Inventory of Existing Commercial Substances
  • Who can preregister and the procedures for doing so
  • Why a company should preregister and what the penalties are if they don’t
  • Best practices for selecting and working with a European representative
  • The potential usefulness of trade association consortia
  • The various methods for calculating volumes and what level of information must be provided

This presentation includes detailed instructions on how to comply with the preregistration requirements in order for firms to be assured that they can continue to operate in the EU. In addition, the speakers will provide insight into what level of technical detail is required to comply with the regulations.

Register now and you'll get an opportunity to ask your toughest questions during the Q&A session.

This presentation is a must for employees of drug, biotech and medical device firms that want to do business in the EU, including:

  • Regulatory and compliance professionals
  • Supply and product sourcing directors
  • Executive management
  • General and corporate counsel
  • Business development officers
  • International business operations
  • Outside attorneys

Cándido García Molyneux is of counsel in the Brussels office of Covington & Burling. His practice focuses on EC environmental law, Spanish food and drug law and international trade law. He advises clients on legal issues concerning environmental product regulation, chemical law, waste management, Spanish medicines and cosmetics rules, and international trade law and non-tariff trade barriers. Cándido was actively involved in the legislative process resulting in the REACH regulation for several companies and trade associations, and advises clients on the impact of the new regime, particularly the implications for downstream uses of chemicals.

Peter Bogaert is a partner based in the Brussels office of Covington & Burling, with a broad European life sciences practice. He has detailed regulatory expertise under EC and national laws, handles legislative and other policy assignments, and provides strategic advice. He also represents life sciences companies before the European Courts in Luxembourg and in local litigation in Belgium. Peter’s practice covers pharmaceuticals, biotechnology, medical devices, special foods and feed, cosmetics and other consumer products. He represents numerous innovative life sciences companies, including start-ups, as well as several industry associations.

Register now!

Date: July 7–25, 2008
Location: Your office or conference room (no need to travel!)
Time: Anytime

Gather your team for maximum benefit! Your investment is for one dial-in.

Interested in registering multiple sites?
Call (888) 838-5578 in the U.S. or +1 (703) 538-7600 globally
to learn about our special multisite discount.

We accept American Express, Visa and MasterCard. Make checks payable to FDAnews.

Or, register by phone: toll free (888) 838-5578 (inside the U.S.) or +1 (703) 538-7600

Cancellations/Substitutions
Registrations may not be cancelled. Please contact customer service to make any substitutions.